Periventricular leukomalacia (PVL) is a major neuropathologic brain injury in premature infants and the leading cause of cerebral palsy. It underlies most of the neurologic morbidity (motor, cognitive, attention, behavioral and visual deficits) encountered in survivors of premature birth. A major pathogenic factor is maturation-dependent vulnerability of the oligodendroglial precursor cell (OPC) that are vulnerable to attack by free radicals generated by hypoxic ischemic injury. Microglia and astroglia are involved in PVL pathogenesis. NF-kB has many important physiological beneficial functions but has harmful inflammatory functions as well. I am currently studying the inhibition of microglial NF-kB and astroglial NF-kB as a novel therapeutic approach for PVL, in a hypoxic-ischemic mouse model of PVL. My studies focused on developing a new prophylactic/ therapeutic approach for PVL which can significantly reduce brain injury after hypoxic-ischemic insults manifested as improvement in long term motor and cognitive functions of the growing neonate.